Targeted Therapy — When You Have Autoimmune Disease

Generally, yes. Checkpoint inhibitors work by broadly activating the immune system, which is what makes them more likely to worsen autoimmune conditions. Targeted drugs block specific molecular pathways involved in cancer growth and do not turn the immune system on in the same way. That said, some targeted agents do have immune-related effects, and your team will factor in the specific drug being recommended when assessing your individual risk.

Some will, some will not. Steroids, DMARDs such as methotrexate and hydroxychloroquine, and biological agents such as anti-TNF treatments are all handled differently depending on what targeted therapy you are receiving. Some need to be paused, some continued, and some adjusted in dose. Your oncologist and your rheumatologist need to review your complete medication list together before treatment starts. Never stop an autoimmune medication without asking your treating team first — stopping abruptly can itself trigger a flare.

This depends on your specific condition and the targeted therapy you are receiving, but monitoring typically includes regular blood tests for liver and kidney function, blood counts, and markers relevant to your autoimmune condition. You will also be asked to report any new joint pain, skin changes, eye symptoms, or other signs that your autoimmune disease may be becoming more active. The monitoring schedule is usually more frequent than for people without a pre-existing condition.

It can happen. While targeted therapy generally carries a lower risk than immunotherapy, some targeted drugs do cause immune-related side effects, and in people with pre-existing autoimmune disease those effects may be more pronounced or harder to distinguish from a flare. Tell your team immediately if you notice your autoimmune symptoms worsening after starting cancer treatment. Early reporting gives your team the most options for managing it.

Your oncologist should loop in the specialist who manages your autoimmune condition — your rheumatologist, gastroenterologist, neurologist, or other relevant specialist. Decisions about pausing or adjusting your autoimmune medications, monitoring during cancer treatment, and managing any flare that occurs are best made with both teams involved. If your specialists do not already communicate with each other, ask your oncologist to initiate that contact before treatment starts.

Tell your oncologist before starting any cancer treatment. A current flare does not automatically delay your cancer care — the urgency of the cancer diagnosis is factored into the decision — but it does change the plan. Your team may aim to bring the flare under better control first, adjust the treatment approach, or put a closer monitoring plan in place. Starting cancer therapy during an active flare without disclosing it is the scenario to avoid.

In most cases, the autoimmune condition itself does not change how well the cancer responds to targeted therapy. What determines response is the molecular target in your tumour — the marker or mutation the drug is designed to hit — not the presence of an autoimmune condition. Where autoimmune disease can affect outcomes is through treatment interruptions: if flares, drug interactions, or side effects repeatedly force pauses in treatment, that can affect cumulative exposure. Keeping both conditions well managed protects against that.

Yes. Targeted therapy at CION is administered as day care across its centres, and your treatment plan will be designed in coordination with your existing specialist. If response-assessment imaging such as PET-CT is needed, it is coordinated with partner imaging centres. Your oncology team will also discuss any additional monitoring your autoimmune condition requires and how that fits into your overall plan.